TrialBMJ open2024

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.

Chia-Chi Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.